Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Graefe's Archive for Clinical and Experimental Ophthalmology
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology 1/2012

01.01.2012 | Review Article

Recent trends in the management of maculopathy secondary to pathological myopia

verfasst von: D. Mitry, H. Zambarakji

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

Pathological myopia is a frequent cause of secondary visual disturbance in young individuals worldwide. Myopic maculopathy describes a spectrum of clinical changes that comprise the main cause of visual loss among highly myopic individuals. Our aim is to describe current trends in the medical and surgical management of maculopathy secondary to pathological myopia.

Methods

The epidemiology, natural history, medical and surgical treatment modalities for choroidal neovascular membrane (CNV) and vitreomacular disorders secondary to pathological myopia (PM) are reviewed and evaluated.

Results

The medical and surgical treatment modalities in the management of myopic maculopathy have evolved over time. Laser photocoagulation, photodynamic therapy with verteporfin and other medical treatments have been superseded by the use of anti-vascular endothelial growth factor in the management of CNV secondary to PM. Surgical treatments are beneficial in the treatment of vitreomacular interface disorders such as macular hole retinal detachment and macular traction; however, primary success rates remain lower than those for non-myopic individuals.

Conclusions

This updated clinical perspective demonstrates that CNV and vitreomacular disorders in pathological myopia are treatable conditions. There are numerous medical and surgical interventions that have significantly improved the outcome of myopic maculopathy and several others currently under investigation. Nonetheless, as technology advances, further well-designed studies are necessary to establish a uniform evidence-based approach for classification and treatment.
Literatur
1.
2.
Yamamoto I, Rogers AH, Reichel E, Yates PA, Duker JS (2007) Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia. Br J Ophthalmol 91:157–160PubMedCrossRef
3.
Tano Y (2002) Pathologic myopia: where are we now? Am. J Ophthalmol 134:645–660
4.
Yoshida T, Ohno-Matsui K, Ohtake Y, Takashima T, Futagami S, Baba T, Yasuzumi K, Tokoro T, Mochizuki M (2002) Long-term visual prognosis of choroidal neovascularization in high myopia: a comparison between age groups. Ophthalmology 109:712–719PubMedCrossRef
5.
Verteporfin in Photodynamic Therapy Study Group (2001) Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial--VIP report no. 1. Ophthalmology 108:841–852CrossRef
6.
Yoshida T, Ohno-Matsui K, Yasuzumi K, Kojima A, Shimada N, Futagami S, Tokoro T, Mochizuki M (2003) Myopic choroidal neovascularization: a 10-year follow-up. Ophthalmology 110:1297–1305PubMedCrossRef
7.
Grossniklaus HE, Green WR (1992) Pathologic findings in pathologic myopia. Retina 12:127–133PubMedCrossRef
8.
Yamada M, Hiratsuka Y, Roberts CB, Pezzullo ML, Yates K, Takano S, Miyake K, Taylor HR (2010) Prevalence of visual impairment in the adult Japanese population by cause and severity and future projections. Ophthalmic Epidemiol 17:50–57PubMedCrossRef
9.
Hsu WM, Cheng CY, Liu JH, Tsai SY, Chou P (2004) Prevalence and causes of visual impairment in an elderly Chinese population in Taiwan: the Shihpai Eye Study. Ophthalmology 111:62–69PubMedCrossRef
10.
Kempen JH, Mitchell P, Lee KE, Tielsch JM, Broman AT, Taylor HR, Ikram MK, Congdon NG, O’Colmain BJ (2004) The prevalence of refractive errors among adults in the United States, Western Europe, and Australia. Arch Ophthalmol 122:495–505PubMedCrossRef
11.
Hornbeak DM, Young TL (2009) Myopia genetics: a review of current research and emerging trends. Curr Opin Ophthalmol 20:356–362PubMedCrossRef
12.
13.
Hayashi K, Ohno-Matsui K, Shimada N, Moriyama M, Kojima A, Hayashi W, Yasuzumi K, Nagaoka N, Saka N, Yoshida T, Tokoro T, Mochizuki M (2010) Long-term pattern of progression of myopic maculopathy: a natural history study. Ophthalmology 117(1595–611):1611
14.
Shih YF, Ho TC, Hsiao CK, Lin LL (2006) Visual outcomes for high myopic patients with or without myopic maculopathy: a 10 year follow up study. Br J Ophthalmol 90:546–550PubMedCrossRef
15.
Avila MP, Weiter JJ, Jalkh AE, Trempe CL, Pruett RC, Schepens CL (1984) Natural history of choroidal neovascularization in degenerative myopia. Ophthalmology 91:1573–1581PubMed
16.
Vongphanit J, Mitchell P, Wang JJ (2002) Prevalence and progression of myopic retinopathy in an older population. Ophthalmology 109:704–711PubMedCrossRef
17.
Soubrane G, Coscas GJ (1994) Choroidal neovascular membranes in degenerative myopia. In: Ryan SJ (ed) Retina. Mosby, St Louis, pp 1143–1157
18.
Cohen SY, Laroche A, Leguen Y, Soubrane G, Coscas GJ (1996) Etiology of choroidal neovascularization in young patients. Ophthalmology 103:1241–1244PubMed
19.
Hayashi K, Ohno-Matsui K, Yoshida T, Kobayashi K, Kojima A, Shimada N, Yasuzumi K, Futagami S, Tokoro T, Mochizuki M (2005) Characteristics of patients with a favorable natural course of myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 243:13–19PubMedCrossRef
20.
Kojima A, Ohno-Matsui K, Teramukai S, Yoshida T, Ishihara Y, Kobayashi K, Shimada N, Yasuzumi K, Futagami S, Tokoro T, Mochizuki M (2004) Factors associated with the development of chorioretinal atrophy around choroidal neovascularization in pathologic myopia. Graefes Arch Clin Exp Ophthalmol 242:114–119PubMedCrossRef
21.
Jalkh AE, Weiter JJ, Trempe CL, Pruett RC, Schepens CL (1987) Choroidal neovascularization in degenerative myopia: role of laser photocoagulation. Ophthalmic Surg 18:721–725PubMed
22.
Secretan M, Kuhn D, Soubrane G, Coscas G (1997) Long-term visual outcome of choroidal neovascularization in pathologic myopia: natural history and laser treatment. Eur J Ophthalmol 7:307–316PubMed
23.
Johnson DA, Yannuzzi LA, Shakin JL, Lightman DA (1998) Lacquer cracks following laser treatment of choroidal neovascularization in pathologic myopia. Retina 18:118–124PubMedCrossRef
24.
Schmidt-Erfurth U, Hasan T (2000) Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol 45:195–214PubMedCrossRef
25.
Schmidt-Erfurth U, Laqua H, Schlotzer-Schrehard U, Viestenz A, Naumann GO (2002) Histopathological changes following photodynamic therapy in human eyes. Arch Ophthalmol 120:835–844PubMed
26.
Blinder KJ, Blumenkranz MS, Bressler NM, Bressler SB, Donato G, Lewis H, Lim JI, Menchini U, Miller JW, Mones JM, Potter MJ, Pournaras C, Reaves A, Rosenfeld P, Schachat AP, Schmidt-Erfurth U, Sickenberg M, Singerman LJ, Slakter JS, Strong HA, Virgili G, Williams GA (2003) Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial–VIP report no. 3. Ophthalmology 110:667–673PubMedCrossRef
27.
Lam DS, Chan WM, Liu DT, Fan DS, Lai WW, Chong KK (2004) Photodynamic therapy with verteporfin for subfoveal choroidal neovascularisation of pathologic myopia in Chinese eyes: a prospective series of 1 and 2 year follow up. Br J Ophthalmol 88:1315–1319PubMedCrossRef
28.
Ergun E, Heinzl H, Stur M (2004) Prognostic factors influencing visual outcome of photodynamic therapy for subfoveal choroidal neovascularization in pathologic myopia. Am J Ophthalmol 138:434–438PubMedCrossRef
29.
Lam DS, Liu DT, Fan DS, Lai WW, So SF, Chan WM (2005) Photodynamic therapy with verteporfin for juxtafoveal choroidal neovascularization secondary to pathologic myopia—1-year results of a prospective series. Eye 19:834–840PubMedCrossRef
30.
Pece A, Vadala M, Isola V, Matranga D (2007) Photodynamic therapy with verteporfin for juxtafoveal choroidal neovascularization in pathologic myopia: a long-term follow-up study. Am J Ophthalmol 143:449–454PubMedCrossRef
31.
Augustin AJ, Schmidt-Erfurth U (2006) Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. Ophthalmology 113:14–22PubMedCrossRef
32.
Chaudhary V, Mao A, Hooper PL, Sheidow TG (2007) Triamcinolone acetonide as adjunctive treatment to verteporfin in neovascular age-related macular degeneration: a prospective randomized trial. Ophthalmology 114:2183–2189PubMedCrossRef
33.
Marticorena J, Gomez-Ulla F, Fernandez M, Pazos B, Rodriguez-Cid MJ, Sanchez-Salorio M (2006) Combined photodynamic therapy and intravitreal triamcinolone acetonide for the treatment of myopic subfoveal choroidal neovascularization. Am J Ophthalmol 142:335–337PubMedCrossRef
34.
Marticorena J, Gomez-Ulla F, Romano MR, Luna I (2007) Repeated pseudoendophthalmitis after combined photodynamic therapy and intravitreal triamcinolone. Graefes Arch Clin Exp Ophthalmol 245:1403–1404PubMedCrossRef
35.
Chan WM, Lai TY, Wong AL, Liu DT, Lam DS (2007) Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study. Br J Ophthalmol 91:174–179PubMedCrossRef
36.
Bennett MD, Yee W (2007) Pegaptanib for myopic choroidal neovascularization in a young patient. Graefes Arch Clin Exp Ophthalmol 245:903–905PubMedCrossRef
37.
38.
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342PubMedCrossRef
39.
Sakaguchi H, Ikuno Y, Gomi F, Kamei M, Sawa M, Tsujikawa M, Oshima Y, Kusaka S, Tano Y (2007) Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia. Br J Ophthalmol 91:161–165PubMedCrossRef
40.
Cohen SY (2009) Anti-VEGF drugs as the 2009 first-line therapy for choroidal neovascularization in pathologic myopia. Retina 29:1062–1066PubMedCrossRef
41.
Gharbiya M, Allievi F, Mazzeo L, Gabrieli CB (2009) Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results. Am J Ophthalmol 147:84–93PubMedCrossRef
42.
Ikuno Y, Sayanagi K, Soga K, Sawa M, Tsujikawa M, Gomi F, Tano Y (2009) Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results. Am J Ophthalmol 147:94–100PubMedCrossRef
43.
Wu PC, Chen YJ (2009) Intravitreal injection of bevacizumab for myopic choroidal neovascularization: 1-year follow-up. Eye 23:2042–2045PubMedCrossRef
44.
Ruiz-Moreno JM, Montero JA, Arias L, Araiz J, Gomez-Ulla F, Silva R, Pinero DP (2010) Twelve-month outcome after one intravitreal injection of bevacizumab to treat myopic choroidal neovascularization. Retina 30:1609–1615PubMedCrossRef
45.
Chan WM, Lai TY, Liu DT, Lam DS (2009) Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study. Br J Ophthalmol 93:150–154PubMedCrossRef
46.
Ruiz-Moreno JM, Montero JA, Gomez-Ulla F, Ares S (2009) Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcome. Br J Ophthalmol 93:448–451PubMedCrossRef
47.
Hayashi K, Ohno-Matsui K, Teramukai S, Shimada N, Moriyama M, Hayashi W, Yoshida T, Tokoro T, Mochizuki M (2009) Comparison of visual outcome and regression pattern of myopic choroidal neovascularization after intravitreal bevacizumab or after photodynamic therapy. Am J Ophthalmol 148:396–408PubMedCrossRef
48.
Ikuno Y, Nagai Y, Matsuda S, Arisawa A, Sho K, Oshita T, Takahashi K, Uchihori Y, Gomi F (2010) Two-year visual results for older Asian women treated with photodynamic therapy or bevacizumab for myopic choroidal neovascularization. Am J Ophthalmol 149:140–146PubMedCrossRef
49.
Baba T, Kubota-Taniai M, Kitahashi M, Okada K, Mitamura Y, Yamamoto S (2010) Two-year comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularisation. Br J Ophthalmol 94:864–870PubMedCrossRef
50.
Yoon JU, Byun YJ, Koh HJ (2010) Intravitreal anti-VEGF versus photodynamic therapy with verteporfin for treatment of myopic choroidal neovascularization. Retina 30:418–424PubMedCrossRef
51.
Ziemssen F, Inhoffen W, Voelcker M, Grisanti S, Szurman P, Bartz-Schmidt KU, Gelisken F; Tuebingen Bevacizumab Study Group (2007) Intravitreous bevacizumab monotherapy vs combined therapy (bevacizumab + PDT) of choroidal neovascularization in pathological myopia: outcome and re-treatment. Invest Ophthalmol Vis Sci 48:3397
52.
Battista C, Nardoni S, Romani A (2009) Combined intravitreal avastin injection and photodynamic therapy for the treatment of macular choroidal neovascularization in pathological myopia. Invest Ophthalmol Vis Sci 50:2266
53.
Heier JS, Brown D, Ciulla T, Abraham P, Bankert JM, Chong S, Daniel PE Jr, Kim IK (2011) Ranibizumab for choroidal neovascularization secondary to causes other than age-related macular degeneration: a phase I clinical trial. Ophthalmology 118:111–118PubMedCrossRef
54.
Konstantinidis L, Mantel I, Pournaras JA, Zografos L, Ambresin A (2009) Intravitreal ranibizumab (Lucentis) for the treatment of myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 247:311–318PubMedCrossRef
55.
Silva RM, Ruiz-Moreno JM, Nascimento J, Carneiro A, Rosa P, Barbosaa A, Carvalheira F, Abreu JR, Cunha-Vaz JG (2008) Short-term efficacy and safety of intravitreal ranibizumab for myopic choroidal neovascularization. Retina 28:1117–1123PubMedCrossRef
56.
Mones JM, Amselem L, Serrano A, Garcia M, Hijano M (2009) Intravitreal ranibizumab for choroidal neovascularization secondary to pathologic myopia: 12-month results. Eye (Lond) 23:1275–1280CrossRef
57.
Silva RM, Ruiz-Moreno JM, Rosa P, Carneiro A, Nascimento J, Rito LF, Cachulo ML, Carvalheira F, Murta JN (2010) Intravitreal ranibizumab for myopic choroidal neovascularization: 12-month results. Retina 30:407–412PubMedCrossRef
58.
Lalloum F, Souied EH, Bastuji-Garin S, Puche N, Querques G, Glacet-Bernard A, Coscas G, Soubrane G, Leveziel N (2010) Intravitreal ranibizumab for choroidal neovascularization complicating pathologic myopia. Retina 30:399–406PubMedCrossRef
59.
Cornut PL, Poli M, Feldman A, El CH, Swalduz B, Burillon C, Denis P (2010) Intravitreal ranibizumab for choroidal neovascularization secondary to pathological myopia: 12-month results. J Fr Ophtalmol 33:327–333PubMedCrossRef
60.
Gharbiya M, Giustolisi R, Allievi F, Fantozzi N, Mazzeo L, Scavella V, Gabrieli CB (2010) Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab–a randomized controlled trial. Am J Ophthalmol 149:458–464PubMedCrossRef
61.
Wong TP, Brown DM, Benz MS (2007) Phase II clinical trial of intravenous combretastatin a4 phosphate in patients with subfoveal choroidal neovascular membranes (CNV) in pathologic myopia. Invest Ophthalmol Vis Sci 48:1457CrossRef
62.
Heier JS, CLEAR-IT (2009) CLEAR-IT 2: phase 2, randomized, controlled dose-and interval-ranging study of intravitreal VEGF Trap Eye in patients with neovascular age-related macular degeneration: predictive factors for visual acuity outcome at one year. Invest Ophthalmol Vis Sci 50:1255
63.
Costa RA, Calucci D, Teixeira LF, Cardillo JA, Bonomo PP (2003) Selective occlusion of subfoveal choroidal neovascularization in pathologic myopia using a new technique of ingrowth site treatment. Am J Ophthalmol 135:857–866PubMedCrossRef
64.
Kaiser PK, Symons RC, Shah SM, Quinlan EJ, Tabandeh H, Do DV, Reisen G, Lockridge JA, Short B, Guerciolini R, Nguyen QD (2010) RNAi-based treatment for neovascular age-related macular degeneration by Sirna-027. Am J Ophthalmol 150:33–39PubMedCrossRef
65.
Zhang M, Zhang J, Yan M, Luo D, Zhu W, Kaiser PK, Yu DC (2010) A phase 1 study of KH902, a vascular endothelial growth factor receptor decoy, for exudative age-related macular degeneration. Ophthalmology 118(4):672–678PubMedCrossRef
66.
Ni Z, Hui P (2009) Emerging pharmacologic therapies for wet age-related macular degeneration. Ophthalmologica 223:401–410PubMedCrossRef
67.
Hawkins BS, Miskala PH, Bass EB, Bressler NM, Childs AL, Mangione CM, Marsh MJ (2004) Surgical removal vs observation for subfoveal choroidal neovascularization, either associated with the ocular histoplasmosis syndrome or idiopathic: II. Quality-of-life findings from a randomized clinical trial: SST Group H Trial: SST Report No. 10. Arch Ophthalmol 122:1616–1628PubMedCrossRef
68.
Uemura A, Thomas MA (2000) Subretinal surgery for choroidal neovascularization in patients with high myopia. Arch Ophthalmol 118:344–350PubMed
69.
Ruiz-Moreno JM, De la Vega C (2001) Surgical removal of subfoveal choroidal neovascularisation in highly myopic patients. Br J Ophthalmol 85:1041–1043PubMedCrossRef
70.
Hamelin N, Glacet-Bernard A, Brindeau C, Mimoun G, Coscas G, Soubrane G (2002) Surgical treatment of subfoveal neovascularization in myopia: macular translocation vs surgical removal. Am J Ophthalmol 133:530–536PubMedCrossRef
71.
Machemer R, Steinhorst UH (1993) Retinal separation, retinotomy, and macular relocation: II. A surgical approach for age-related macular degeneration? Graefes Arch Clin Exp Ophthalmol 231:635–641PubMedCrossRef
72.
Kamei M, Tano Y, Yasuhara T, Ohji M, Lewis H (2004) Macular translocation with chorioscleral outfolding: 2-year results. Am J Ophthalmol 138:574–581PubMedCrossRef
73.
Takano M, Kishi S (1999) Foveal retinoschisis and retinal detachment in severely myopic eyes with posterior staphyloma. Am J Ophthalmol 128:472–476PubMedCrossRef
74.
Benhamou N, Massin P, Haouchine B, Erginay A, Gaudric A (2002) Macular retinoschisis in highly myopic eyes. Am J Ophthalmol 133:794–800PubMedCrossRef
75.
Gaucher D, Haouchine B, Tadayoni R, Massin P, Erginay A, Benhamou N, Gaudric A (2007) Long-term follow-up of high myopic foveoschisis: natural course and surgical outcome. Am J Ophthalmol 143:455–462PubMedCrossRef
76.
Scott IU, Moshfeghi AA, Flynn HW Jr (2006) Surgical management of macular retinoschisis associated with high myopia. Arch Ophthalmol 124:1197–1199PubMedCrossRef
77.
Kobayashi H, Kishi S (2003) Vitreous surgery for highly myopic eyes with foveal detachment and retinoschisis. Ophthalmology 110:1702–1707PubMedCrossRef
78.
Baba T, Tanaka S, Maesawa A, Teramatsu T, Noda Y, Yamamoto S (2006) Scleral buckling with macular plombe for eyes with myopic macular retinoschisis and retinal detachment without macular hole. Am J Ophthalmol 142:483–487PubMedCrossRef
79.
Ward B, Tarutta EP, Mayer MJ (2009) The efficacy and safety of posterior pole buckles in the control of progressive high myopia. Eye 23:2169–2174PubMedCrossRef
80.
Zhu Z, Ji X, Zhang J, Ke G (2009) Posterior scleral reinforcement in the treatment of macular retinoschisis in highly myopic patients. Clin Experiment Ophthalmol 37:660–663PubMedCrossRef
81.
Wolfensberger TJ, Gonvers M (2000) Surgical treatment of retinal detachment owing to macular hole. Semin Ophthalmol 15:122–127PubMedCrossRef
82.
Morita H, Ideta H, Ito K, Yonemoto J, Sasaki K, Tanaka S (1991) Causative factors of retinal detachment in macular holes. Retina 11:281–284PubMedCrossRef
83.
Akiba J, Konno S, Yoshida A (1999) Retinal detachment associated with a macular hole in severely myopic eyes. Am J Ophthalmol 128:654–655PubMedCrossRef
84.
Ikuno Y, Sayanagi K, Oshima T, Gomi F, Kusaka S, Kamei M, Ohji M, Fujikado T, Tano Y (2003) Optical coherence tomographic findings of macular holes and retinal detachment after vitrectomy in highly myopic eyes. Am J Ophthalmol 136:477–481PubMedCrossRef
85.
Ichibe M, Yoshizawa T, Murakami K, Ohta M, Oya Y, Yamamoto S, Funaki S, Funaki H, Ozawa Y, Baba E, Abe H (2003) Surgical management of retinal detachment associated with myopic macular hole: anatomic and functional status of the macula. Am J Ophthalmol 136:277–284PubMedCrossRef
86.
Ikuno Y, Tano Y (2006) Vitrectomy for macular holes associated with myopic foveoschisis. Am J Ophthalmol 141:774–776PubMedCrossRef
87.
Kadonosono K, Yazama F, Itoh N, Uchio E, Nakamura S, Akura J, Sawada H, Ohno S (2001) Treatment of retinal detachment resulting from myopic macular hole with internal limiting membrane removal. Am J Ophthalmol 131:203–207PubMedCrossRef
88.
Seike C, Kusaka S, Sakagami K, Ohashi Y (1997) Reopening of macular holes in highly myopic eyes with retinal detachments. Retina 17:2–6PubMedCrossRef
89.
Tabandeh H, Smiddy WE, Mello M, Alexandrakis G, Flynn HW Jr, Gregor Z, Schiffman J (2001) Surgery for idiopathic macular holes associated with extensive subretinal fluid. Retina 21:15–19PubMedCrossRef
90.
Chen YP, Chen TL, Yang KR, Lee WH, Kuo YH, Chao AN, Wu WC, Chen KJ, Lai CC (2006) Treatment of retinal detachment resulting from posterior staphyloma-associated macular hole in highly myopic eyes. Retina 26:25–31PubMedCrossRef
91.
Lu L, Li Y, Cai S, Yang J (2002) Vitreous surgery in highly myopic retinal detachment resulting from a macular hole. Clin Experiment Ophthalmol 30:261–265PubMedCrossRef
92.
Cheung BT, Lai TY, Yuen CY, Lai WW, Tsang CW, Lam DS (2007) Results of high-density silicone oil as a tamponade agent in macular hole retinal detachment in patients with high myopia. Br J Ophthalmol 91:719–721PubMedCrossRef
93.
Nishimura A, Kimura M, Saito Y, Sugiyama K (2011) Efficacy of primary silicone oil tamponade for the treatment of retinal detachment caused by macular hole in high myopia. Am J Ophthalmol 151:148–155PubMedCrossRef
94.
Ando F, Ohba N, Touura K, Hirose H (2007) Anatomical and visual outcomes after episcleral macular buckling compared with those after pars plana vitrectomy for retinal detachment caused by macular hole in highly myopic eyes. Retina 27:37–44PubMedCrossRef
95.
Sasoh M, Yoshida S, Ito Y, Matsui K, Osawa S, Uji Y (2000) Macular buckling for retinal detachment due to macular hole in highly myopic eyes with posterior staphyloma. Retina 20:445–449PubMed
96.
Ripandelli G, Coppe AM, Fedeli R, Parisi V, D’Amico DJ, Stirpe M (2001) Evaluation of primary surgical procedures for retinal detachment with macular hole in highly myopic eyes: a comparison [corrected] of vitrectomy versus posterior episcleral buckling surgery. Ophthalmology 108:2258–2264PubMedCrossRef
97.
Devin F, Tsui I, Morin B, Duprat JP, Hubschman JP (2011) T-shaped scleral buckle for macular detachments in high myopes. Retina 31:177–180PubMedCrossRef
Metadaten
Titel
Recent trends in the management of maculopathy secondary to pathological myopia
verfasst von
D. Mitry
H. Zambarakji
Publikationsdatum
01.01.2012
Verlag
Springer-Verlag
Erschienen in
Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 1/2012
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-011-1889-0

Weitere Artikel der Ausgabe 1/2012

Graefe's Archive for Clinical and Experimental Ophthalmology 1/2012 Zur Ausgabe

Letter to the Editor

Usefulness of magnetic resonance imaging in a patient with diplopia after cataract surgery

Cornea

UVA-riboflavin photochemical therapy of bacterial keratitis: a pilot study

Cornea

Assessment of the reliability of endothelial cell-density estimates in the presence of pseudoguttata

Letter to the Editor

Ab externo laser photocoagulation for the treatment of spontaneous iris stromal cyst

Basic Science

Expression of Stat3 and indoleamine 2, 3-dioxygenase in cornea keratocytes as factor of ocular immune privilege

Letter to the Editor

Orbital venous hemangioma

Neu im Fachgebiet Augenheilkunde

08.04.2024 | Therapieverfahren in der Augenheilkunde | CME

Ophthalmika in der Schwangerschaft

08.03.2024 | Vitrektomie | Originalien

Operative Therapie und Keimnachweis bei endogener Endophthalmitis
Datenauswertung aus 5 Augenkliniken

04.03.2024 | Vitrektomie | Leitthema

Bakterielle endogene Endophthalmitis
Erregerspektrum und medikamentöse Therapie

27.02.2024 | Erkrankungen der Hornhaut | CME

Bestmögliche Wundheilung der Kornea dank optimaler pharmakologischer Therapie

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen